Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis

This publication has 98 references indexed in Scilit:

• 15‐Deoxy‐Δ^12,14‐PGJ₂, but not troglitazone, modulates IL‐1β effects in human chondrocytes by inhibiting NF‐κB and AP‐1 activation pathways
  FEBS Letters, 2001
• Less Extrahepatic Induction of Fatty Acid β-Oxidation Enzymes by PPARα
  Biochemical and Biophysical Research Communications, 2000
• Guilt by association
  Nature Genetics, 2000
• Regulation of Gene Expression by Activation of the Peroxisome Proliferator-Activated Receptor γ with Rosiglitazone (BRL 49653) in Human Adipocytes
  Biochemical and Biophysical Research Communications, 1999
• Thiazolidinediones Suppress Endothelin-1 Secretion from Bovine Vascular Endothelial Cells: A New Possible Role of PPARγ on Vascular Endothelial Function
  Biochemical and Biophysical Research Communications, 1999
• Pro12Ala Missense Mutation of the Peroxisome Proliferator Activated Receptor γ and Diabetes Mellitus
  Biochemical and Biophysical Research Communications, 1999
• Cerivastatin in the treatment of mixed hyperlipidemia: the right study
  The American Journal of Cardiology, 1998
• Molecular Scanning of the Human Peroxisome Proliferator Activated Receptor γ (hPPARγ) Gene in Diabetic Caucasians: Identification of a Pro12Ala PPARγ2 Missense Mutation
  Biochemical and Biophysical Research Communications, 1997
• The west of Scotland Coronary Prevention study: A trial of cholesterol reduction in scottish men
  The American Journal of Cardiology, 1995
• Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers
  Biochemical and Biophysical Research Communications, 1992